A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2‐Positive Metastatic Breast Cancer (CCTG IND.229)

BACKGROUND. Immune checkpoint inhibitors are active in a broad range of cancers, including programmed death ligand 1 (PD‐L1)‐positive, triple‐negative, metastatic breast cancer (MBC). Antibody‐dependent cell‐mediated cytotoxicity is a mechanism of action of trastuzumab. We performed a phase Ib trial...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Chia, Stephen, Bedard, Phillipe L., Hilton, John, Amir, Eitan, Gelmon, Karen, Goodwin, Rachel, Villa, Diego, Cabanero, Michael, Tu, Dongsheng, Tsao, Ming, Seymour, Lesley
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853090/
https://ncbi.nlm.nih.gov/pubmed/31420468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0321
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados